These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 11598177)

  • 1. Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions.
    Bayer-Garner IB; Sanderson RD; Dhodapkar MV; Owens RB; Wilson CS
    Mod Pathol; 2001 Oct; 14(10):1052-8. PubMed ID: 11598177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD138/syndecan-1: a useful immunohistochemical marker of normal and neoplastic plasma cells on routine trephine bone marrow biopsies.
    Chilosi M; Adami F; Lestani M; Montagna L; Cimarosto L; Semenzato G; Pizzolo G; Menestrina F
    Mod Pathol; 1999 Dec; 12(12):1101-6. PubMed ID: 10619261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neural cell adhesion molecule expression in plasma cells in bone marrow biopsies and aspirates allows discrimination between multiple myeloma, monoclonal gammopathy of uncertain significance and polyclonal plasmacytosis.
    Martín P; Santón A; Bellas C
    Histopathology; 2004 Apr; 44(4):375-80. PubMed ID: 15049904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flow cytometric evaluation of bone marrow plasma cells using CD19, CD45, CD56, CD38, and CD138 and correlation with bone marrow infiltration ratio in multiple myeloma patients.
    Kara IO; Sahin B; Paydas S; Cetiner S
    Saudi Med J; 2004 Nov; 25(11):1587-92. PubMed ID: 15573184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High heparanase activity in multiple myeloma is associated with elevated microvessel density.
    Kelly T; Miao HQ; Yang Y; Navarro E; Kussie P; Huang Y; MacLeod V; Casciano J; Joseph L; Zhan F; Zangari M; Barlogie B; Shaughnessy J; Sanderson RD
    Cancer Res; 2003 Dec; 63(24):8749-56. PubMed ID: 14695190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD138 (syndecan-1), a plasma cell marker immunohistochemical profile in hematopoietic and nonhematopoietic neoplasms.
    O'Connell FP; Pinkus JL; Pinkus GS
    Am J Clin Pathol; 2004 Feb; 121(2):254-63. PubMed ID: 14983940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone marrow stromal cell interaction reduces syndecan-1 expression and induces kinomic changes in myeloma cells.
    Fuhler GM; Baanstra M; Chesik D; Somasundaram R; Seckinger A; Hose D; Peppelenbosch MP; Bos NA
    Exp Cell Res; 2010 Jul; 316(11):1816-28. PubMed ID: 20307537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induced expression of syndecan-1 in the stroma of head and neck squamous cell carcinoma.
    Mukunyadzi P; Liu K; Hanna EY; Suen JY; Fan CY
    Mod Pathol; 2003 Aug; 16(8):796-801. PubMed ID: 12920224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Syndecan-1 in B lymphoid malignancies.
    Sanderson RD; Børset M
    Ann Hematol; 2002 Mar; 81(3):125-35. PubMed ID: 11904737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proximal promoter of the murine syndecan-1 gene is not sufficient for the developmental pattern of syndecan expression in B lineage cells.
    Volpe CP; Lundgren A; Aints A; Mohamed AJ; Jaakkola P; Christensson B; Gahrton G; Jalkanen M; Smith CI; Dilber MS
    Am J Hematol; 2001 May; 67(1):20-6. PubMed ID: 11279653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Mi15 monoclonal antibody (anti-syndecan-1) is a reliable marker for quantifying plasma cells in paraffin-embedded bone marrow biopsy specimens.
    Costes V; Magen V; Legouffe E; Durand L; Baldet P; Rossi JF; Klein B; Brochier J
    Hum Pathol; 1999 Dec; 30(12):1405-11. PubMed ID: 10667416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Importance of selected laboratory indicators in the differential diagnosis and monitoring of multiple myeloma].
    Maisnar V; Tousková M; Malý J; Krejsek J; Kmonícek M; Kopecký O
    Vnitr Lek; 2002 Apr; 48(4):290-7. PubMed ID: 12061177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of syndecan-1 with tumor grade and histology in primary invasive cervical carcinoma.
    Rintala M; Inki P; Klemi P; Jalkanen M; Grénman S
    Gynecol Oncol; 1999 Dec; 75(3):372-8. PubMed ID: 10600292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of CD138 (syndecan-1) in distinguishing carcinomas from mesotheliomas.
    Saqi A; Yun SS; Yu GH; Alexis D; Taub RN; Powell CA; Borczuk AC
    Diagn Cytopathol; 2005 Aug; 33(2):65-70. PubMed ID: 16007640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tc-99m methoxyisobutylisonitrile bone marrow imaging for predicting the levels of myeloma cells in bone marrow in multiple myeloma: correlation with CD38/CD138 expressing myeloma cells.
    Ak I; Aslan V; Vardareli E; Gülbaş Z
    Ann Hematol; 2003 Feb; 82(2):88-92. PubMed ID: 12601486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma.
    Heider U; Langelotz C; Jakob C; Zavrski I; Fleissner C; Eucker J; Possinger K; Hofbauer LC; Sezer O
    Clin Cancer Res; 2003 Apr; 9(4):1436-40. PubMed ID: 12684416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Syndecan-1 expression in malignant mesothelioma: correlation with cell differentiation, WT1 expression, and clinical outcome.
    Kumar-Singh S; Jacobs W; Dhaene K; Weyn B; Bogers J; Weyler J; Van Marck E
    J Pathol; 1998 Nov; 186(3):300-5. PubMed ID: 10211120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival.
    Andersen NF; Standal T; Nielsen JL; Heickendorff L; Borset M; Sørensen FB; Abildgaard N
    Br J Haematol; 2005 Jan; 128(2):210-7. PubMed ID: 15638855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of proteoglycan core proteins in human bone marrow stroma.
    Schofield KP; Gallagher JT; David G
    Biochem J; 1999 Nov; 343 Pt 3(Pt 3):663-8. PubMed ID: 10527946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells.
    Yata K; Yaccoby S
    Leukemia; 2004 Nov; 18(11):1891-7. PubMed ID: 15385929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.